Over 15 years: the advancement of transcatheter mitral valve repair

Paolo Denti, Alessandra Sala, Igor Belluschi, Ottavio Alfieri

Department of Cardiovascular and Thoracic Surgery, San Raffaele University Hospital, Milan, Italy

Correspondence to: Paolo Denti, MD. Department of Cardiovascular and Thoracic Surgery, San Raffaele University Hospital, Via Olgettina 60, 20132, Milan, Italy. Email: denti.paolo@hsr.it.

Patients with severe symptomatic mitral regurgitation, if left untreated, have a poor prognosis. In those patients not eligible for mitral valve (MV) surgery, percutaneous repair may improve clinical outcomes. In the past 15 years several devices have been developed to address different MV lesions. This manuscript will review the advancement of transcatheter MV repair through the years, focusing on technologies for which consistent clinical data is available.

Keywords: Mitral regurgitation; mitral valve (MV); MV repair; transcatheter MV repair


doi: 10.21037/acs-2020-mv-18

View this article at: http://dx.doi.org/10.21037/acs-2020-mv-18

Introduction

Mitral valve regurgitation (MR) is the second most common valvular pathology in patients with cardiac valve disease, secondary only to aortic valve stenosis, with a reported prevalence of more than 10% in people older than 75 years of age (1,2). Severe MR, if left untreated, is associated with progressive left ventricular (LV) dysfunction and congestive heart failure, leading to a high degree of morbidity and mortality (3,4).

Considering the differences in prognosis, indications for treatment and management, it is important to distinguish primary mitral regurgitation (PMR) from secondary mitral regurgitation (SMR). Primary, or organic, MR is characterized by abnormalities in the mitral valve (MV) apparatus, as seen in degenerative disease, rheumatic disease, infective endocarditis and toxic valvulopathy. On the contrary, secondary, or functional MR, is characterized by preserved valvular morphology, in presence of LV remodeling, displacement of papillary muscles, leaflet tethering and annular dilatation (5-8).

Surgery remains the mainstay of treatment in case of PMR (9); on the contrary it does not play a leading role in SMR, leaving an important window for transcatheter treatments (10,11).

Current European guidelines (12) recommend surgical treatment of severe symptomatic PMR (Class I). Surgery is also indicated in the case of asymptomatic individuals with PMR and other predictors of worse outcome, such as atrial fibrillation and LV dysfunction [defined as ejection fraction (EF) ≤60% and/or LV end systolic diameter (ESD) ≥45 mm]. For MR, surgery is indicated in patients with severe MR undergoing revascularization with evidence of myocardial viability.

Regardless of the etiology and type of lesions, left untreated severe MR has a poor prognosis, worse quality of life and increase in heart failure symptoms (3). However, in patients with severely reduced LVEF, surgical MV repair or replacement does not lower the rate of hospitalizations and death, and is associated with high surgical risk. Furthermore, it has been estimated that approximately 50% of patients with severe MR are not eligible for a surgical approach due to age, comorbidities and surgical risk (13). This large unmet clinical need for less-invasive therapeutic options led to the development of transcatheter approaches. These patients may benefit from such procedures, in order to improve symptomatology, quality of life and functional class.

Indeed, since the advent of transcatheter treatment
of aortic valve pathology, great interest has grown in the development of devices capable of addressing MV pathologies. In the past 15 years, technological improvements in percutaneous MV interventions have made such procedures feasible and safe, and nowadays frequently used in daily clinical practice (14).

In the current review we aim at analyzing the advancements of transcatheter MV repair within the past 15 years, focusing on technologies for which consistent clinical data is available. Particular attention is devoted to achieve a tailored approach choosing the right device according to the specific lesion.

**Transcatheter treatment of MR: a selective approach**

Transcatheter MV repair is one of the greatest evolving fields in valvular heart interventions, with a continuous growing number of devices (15).

Different technologies target the great complexity of the MV and the heterogeneous mechanisms of regurgitation (16) (Figure 1). All devices currently available or under development address the various components permitting a tailored approach, mimicking in to the surgical MV repair, as single or possibly combined approaches. The majority of currently available devices can therefore be conveniently categorized into leaflet repair, mitral annuloplasty and chordal implantation (14).

**Figure 1** Timeline of the evolving technologies for transcatheter treatment of mitral valve regurgitation.

Leaflet repair

**MitraClip device**

The MitraClip system (Abbott Vascular, Abbott Park, IL, USA) replicates the surgical edge-to-edge technique for MV repair, introduced by Alfieri in the surgical armamentarium in 1991 (17). The first-in-human implant occurred in 2003 (18) and subsequently achieved CE mark approval in 2008 and FDA approval in 2013. The device is approved in Europe for treatment of PMR and SMR. Nowadays, more than 100,000 patients have been treated with the MitraClip. Current European Guidelines (12) consider MitraClip treatment as a therapeutic option in high surgical risk patients who meet anatomical criteria of suitability (Class IIb). The procedure is performed with a femoral vein access, and the trans-septal puncture is performed by a steerable guide catheter. The entire procedure is conducted under fluoroscopic and transesophageal echocardiographic guidance. The delivery system is then introduced in the left atrium and the MitraClip device is aligned perpendicularly to the coaptation line of the two MV leaflets. The device is advanced within the left ventricle and upon pull-back, the free edges of the MV leaflets are grasped (19).

The device is composed of two cobalt-chromium arms; the first version of the device, MitraClip NT, has arms of 17 mm in length and was created for deeper leaflet insertion (Figure 2A). The further version of the device, MitraClip XTR, was modified to 22 mm in length and...
with nitinol gripper lines that enable deeper gripper drop and grasping angle (Figure 2B). The idea behind increasing the length of the clip was to grip more valvular tissue and possibly expand treatment to more unfavorable anatomies. However, grasping more tissue can convey greater tension on the leaflets causing damage. Furthermore, the longer the clip arms the higher the risk of entrapment within the subvalvular apparatus, especially when addressing commissural lesions. The latest innovation consists of the fourth generation MitraClip device (Figure 2C), available in four different clip sizes, with wider arms, controlled grasping and continuous left atrial pressure monitoring. These changes further allow a tailored repair to each patient's anatomy, allowing treatment of a wider range of challenging anatomies.

Several randomized controlled trials have been conducted with the aim of assessing effectiveness and safety of the MitraClip device. The EVEREST II trial (20) (Endovascular Valve Edge-to-edge Repair Study) was the first multicenter randomized clinical trial that studied 279 patients with MR, comparing percutaneous treatment vs. surgical MV repair or replacement. Results showed, at five years, increased safety of the percutaneous approach (15.0% major adverse events in MitraClip group vs. 48.0% in surgical group), and no difference in mortality (18.8% vs. 21.0%). Furthermore, a stable MR reduction and positive LV remodeling following MitraClip implant were seen. However, effectiveness resulted to be higher in the surgical group (44.2% vs. 64.3%; P=0.01) for higher recurrence of MR ≥2+ and higher reinterventions in the MitraClip group.

Numerous other MitraClip registries have demonstrated a high rate of procedural success and favorable short-term
outcomes (Table 1), and many more are still ongoing (21,22).

Recently, transcatheter treatment of SMR has been under the spotlight due to release of two multicenter randomized studies performed in order to assess effectiveness of MitraClip treatment in patients with heart failure and SMR, that remained symptomatic despite maximal medical therapy. Both randomized patients to treatment with medical therapy alone, or MitraClip together with medical therapy. MITRA-FR (23) study results showed MR ≤ 2 in 92% of patients following the procedure and a re-hospitalization rate for heart failure within the first year of follow-up of 55.0% vs. 51.0% in the interventional and control groups, respectively. At twelve months, the mortality rate was 24.0% in the former vs. 22.0% in the latter [hazard ratio (HR), 1.11; 95% CI, 0.69–1.77]. On the contrary, the COAPT study (24), for the first time ever, strongly demonstrated a lower all-cause mortality and reduced hospitalizations for heart failure events in the device group in comparison the control group. The benefits were consistent throughout subgroups, including ischemic and non-ischemic cardiomyopathy, LV volume and function and baseline. Possible explanations for such different results were the considerable amount of missing echocardiographic data at twelve months in the French study, patient selection and length of follow-up.

**PASCAL system**

The PASCAL device (Edwards Lifesciences, Irvine, CA)—from “Paddles, Spacer, Clasps, Alfieri”—was designed to treat MR by overcoming some of the limitations of the previous system. The device has larger paddles with a central spacer in order to maximize leaflet coaptation and the ability to grasp the individual leaflets (Figure 2D). Furthermore, the clasps allow for independent leaflet capture and offer the possibility to finetune leaflet positioning (Figure 2E). Delivery of the device occurs through a transvenous transfemoral access and transseptal approach. The device received CE mark in February 2019, and is still awaiting FDA approval. The multicenter, prospective CLASP trial (25,26) addresses the feasibility of the new Edwards device in patients affected by both PMR and SMR. Mean age was 76.5 years, with the majority of patients having FMR, 51.6% vs. 36.0% with DMR and 8.0% with a mixed etiology. Results showed a low cardiovascular mortality (1.6%) without any stroke events. Furthermore, 98% of patients at follow-up had MR ≤ 2+, among which 86% with MR ≤ 1+, and the great majority of patients resulted in improvement in functional class, with 85% of them being in NYHA Class I/II.

A new randomized trial, the CLASP IID/F has begun enrolment and will aim at comparing the efficacy and safety of the PASCAL device compared to the MitraClip device in patients with significant PMR and SMR. However, results of the first CLASP trial made various questions emerge regarding the role of the two devices. The PASCAL device represents an important advancement in the treatment of MR, and will likely play a converging role together with the MitraClip system. In fact, the MitraClip system has some intrinsic limitations, and it is not suitable for the entire proportion of patients due to anatomical reasons, the so-called EVEREST criteria. Furthermore, the edge-to-edge repair performed with the MitraClip can be demanding in some anatomical settings due to difficult maneuvering of the system (Table 2). The novel leaflet repair device was designed in order to overcome such limitations, trying to expand patient eligibility for repair (27). Additional data on durability and complementary role with the MitraClip device needs to be further investigated.

<table>
<thead>
<tr>
<th>Registry</th>
<th>n</th>
<th>Age</th>
<th>Risk score</th>
<th>NYHA III/IV</th>
<th>LVEF</th>
<th>FMR</th>
<th>Post MR ≤2+</th>
<th>30d mortality</th>
<th>1-year mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td>TRAMI</td>
<td>1,064</td>
<td>75</td>
<td>10%</td>
<td>87%</td>
<td>NA</td>
<td>71%</td>
<td>96%</td>
<td>5.7%</td>
<td>NA</td>
</tr>
<tr>
<td>European sentinel</td>
<td>628</td>
<td>74</td>
<td>20%</td>
<td>86%</td>
<td>43%</td>
<td>72%</td>
<td>98%</td>
<td>3%</td>
<td>15.3%</td>
</tr>
<tr>
<td>ACCESS-EU</td>
<td>567</td>
<td>78</td>
<td>23%</td>
<td>85%</td>
<td>NA</td>
<td>77%</td>
<td>91%</td>
<td>3.4%</td>
<td>17.3%</td>
</tr>
<tr>
<td>EVEREST II and REALISM</td>
<td>351</td>
<td>76</td>
<td>11%</td>
<td>85%</td>
<td>48%</td>
<td>70%</td>
<td>86%</td>
<td>4.8%</td>
<td>22.8%</td>
</tr>
<tr>
<td>GRASP</td>
<td>171</td>
<td>71</td>
<td>7%</td>
<td>81%</td>
<td>37%</td>
<td>78%</td>
<td>93%</td>
<td>0.9%</td>
<td>14%</td>
</tr>
<tr>
<td>MitraSwiss</td>
<td>100</td>
<td>77</td>
<td>17%</td>
<td>82%</td>
<td>48%</td>
<td>62%</td>
<td>85%</td>
<td>4%</td>
<td>15.4%</td>
</tr>
</tbody>
</table>

Table 1 MitraClip registries and outcomes
Reduction of the MV annulus with an undersized ring is the standard surgical treatment for functional MR. Only with annuloplasty it is possible to restore MV competency, improve LV performance, obtain reverse remodeling and decrease symptoms.

Development of less invasive, percutaneous devices, has evolved over the years as a valuable alternative to surgical annuloplasty, especially in high-risk patients. In fact, up to one-third of patients screened for MitraClip are declined leaflet repair due to unfavorable anatomy, including marked annular dilation. The unmet clinical need together with the will to address ineligible patients drove the development of a great variety of devices. Placing greater emphasis on the devices currently available, these can be further subdivided into two groups: direct and indirect annuloplasty systems.

**Indirect annuloplasty devices**

**CARILLON mitral contour system**
The CARILLON device (Cardiac Dimensions, Inc., Kirkland, Washington) was the principal system to be investigated in this subcategory of devices and received CE mark approval in 2011. It consists of a self-expandable nitinol semi-helical distal and proximal anchors connected by a nitinol bridge and delivered through a transjugular venous access (Figure 3A,B). The proximal anchor is positioned at the level of the coronary sinus, while the distal anchor within the great cardiac vein. Upon release the system is capable of plicating the posterior MV annulus to reduce annular dilation and, as a consequence, the degree of MR. The device is therefore indicated in patients with functional MR, and can be easily retrieved and repositioned if MR reduction is not adequate or if coronary artery compromise is detected (28).

Initial studies of the CARILLON device, AMADEUS (28) and TITAN (29) trials have shown good results of this annuloplasty system. The AMADEUS trial, a prospective single-arm feasibility study, showed significant reduction in mitral annulus diameter, decrease in degree of MR by at least one grade, improvement in functional class and quality of life at 24 months follow-up. The second trial performed, the TITAN trial (The Transcatheter Implantation of the Carillon Mitral Annuloplasty Device), was a prospective non-randomized study of patients with functional MR treated with a second-generation device. Fifty-three patients were enrolled, and results reported successful permanent device implantation in 36 patients. Furthermore, there was evidence of significant reduction in degree of MR, including regurgitant volume and effective regurgitant orifice area (EROA). Positive LV remodelling was demonstrated at 12 months, together with improvement in functional class and quality of life at 24 months. In seventeen of the 53 patients, the device could not be permanently implanted due to difficulty cannulating the coronary sinus, ineffective reduction in MR, or compression of the circumflex artery. The TITAN II study (30) was conducted in order to test the newer generation of the modified CARILLON device. A single device fracture was reported, and one year mortality was 23%, with no death adjudicated to be device-related. The modified CARILLON device is currently being evaluated in a multicenter blinded randomized control trial, the REDUCE FMR trial.

Due to the favorable position of the coronary sinus, it is noteworthy to mention other indirect annuloplasty devices developed in the past that took advantage of the same mechanism of action. These include the Monarc device (31) (Edwards Lifesciences, Irvine, California) that was studied in a human trial, but was subsequently halted due to slow enrollment, and the Viacor PTMA system (32) (Viacor, Wilmington, Massachusetts) that was taken off the market due to late, fatal coronary sinus laceration. In

---

**Table 2 Anatomical considerations for MitraClip treatment (EVEREST Criteria)**

| Favorable | Moderate-severe pr severe MR |
| A2-P2 defect |
| Prolapse width <15 mm |
| Flail gap <10 mm |
| Mitral valve orifice area >4 cm² |
| Mobile length posterior leaflet ≥7mm |
| Unfavorable/challenging |
| Commissural lesions |
| Clefts |
| Short posterior leaflet (<5 mm) |
| Mitral valve orifice area <3.5 cm² |
| Severe calcification of grasping zone |
| Leaflet perforations |
| Mitral stenosis Gmed ≥5 mmHg OR active endocarditis |
fact, regardless the “safe” position of the coronary sinus, non-invasive imaging has demonstrated that the separation between the coronary sinus and the mitral apparatus increases significantly in dilated hearts compared to normal hearts, resulting in ineffective MR reduction. This may require increased cinching with a higher probability of compressing the circumflex artery or major branches.

**ARTO device**
The ARTO device: the MVRx ARTO transcatheter annular reduction therapy (MVRX, Inc., Belmont, California) is a system that delivers transvenously two anchors: one through the interatrial septum, the second to the coronary sinus, and acts by reducing the antero-posterior diameter of the mitral annulus (Figure 3C). The MV RepaiR Clinical trial (MAVERIC trial) (33) is a prospective single arm study that evaluated safety and performance of the device in patients affected by functional MR. Promising results of the first patients treated (11/31) have been released, but complete and final results are still pending.

**Mitral loop cerclage catheter system**
The Mitral Loop Cerclage system (34) (Tau-PNU Medical Co, Ltd., Pusan, Korea) is a procedure performed with a double venous access: a femoral vein access and a left subclavian vein one, via a pacemaker-type pocket (Figure 3D). The cerclage is accomplished using a guidewire to enter the coronary sinus and great cardiac vein, and snaring of the wire occurs from the right ventricular outflow tract once crossing of the interventricular septum across the anterior interventricular vein is obtained. A loop is formed around the mitral annular plane and the guidewire is exchanged for a tension device that allows compression of the mitral annulus improving leaflet coaptation. The device contains an integrated coronary artery protection element. The tension locking device is then embedded within the left

---

Figure 3 Indirect annuloplasty devices. (A,B) CARILLON Mitral Contour System; (C) MVRx ARTO (arrows); (D) Mitral Loop Cerclage (arrows).
sub-clavicular pocket.

The first-in-human study (35) was performed on five patients, with successful implantation in four individuals. In one patient the procedure was aborted due to unfavorable anatomy. Implant of the device resulted in immediate reduction of MR grade, which was sustained at six months, together with reduction in left atrial and ventricular chamber volumes. Of note, the major device-related complications were coronary artery occlusion and new bundle branch block.

Even though constant improvements and inventions are being made in the field of indirect annuloplasty for the treatment of functional MR, limited application of such devices is strongly dependent on anatomic variations of both the coronary sinus and coronary anatomy as a whole.

Direct annuloplasty devices

Direct annuloplasty devices more closely reproduce surgical annuloplasty techniques (Figure 4). The posterior annulus is usually only targeted for this purpose, since the anterior MV annulus remains a more challenging structure to target, with its anatomic proximity to the aortic valve.

Cardioband device

The Cardioband system (36) (Valtech Cardio Ltd., Or Yehuda, Israel) is a device delivered via a transvenous transseptal approach, which received CE mark approval in 2015. The mechanism consists in delivering direct sutureless helical anchors on the atrial side of the mitral annulus in order to connect the annuloplasty polyester prosthetic tube, from the antero-lateral to the posteromedial trigone. Following implantation, the diameter of the annulus is reduced by controlling tension on the band, under echocardiographic guidance.

Recent results have been published regarding the largest multicenter study, comprising 60 patients affected by functional MR who underwent Cardioband implantation (37). Early results documented anchor detachment, therefore device modification occurred half-way through the study with net improvement (nine of ten patients occurred prior to device modification). Survival at one year was 87% and no device-related deaths were reported. Furthermore, at one year, MR grade was moderate or less in 61% of patients treated, with a significant improvement in functional class, quality of life and exercise capacity.

Of striking interest is the ongoing pivotal ACTIVE Trial that is designed to demonstrate the superiority of Cardioband and guidelines-directed medical therapy (GDMT) compared to GDMT alone, in patients with clinically significant SMR, with a composite hierarchical endpoint of cardiovascular mortality, heart failure hospitalization, quality of life, and exercise capacity.

It is noteworthy to underline that the Cardioband device has the great advantage of preserving the patient's native anatomy, therefore allowing to keep future repair options open. Furthermore, when considering treatment with multiple device therapies, the Cardioband device has been combined with both double orifice repair with the MitraClip (38) device and chordal replacement in order to maximize MR reduction. Still, several studies have to be made in order to better define the potential future of such combination.

Mitraign annuloplasty system

The Mitralign Percutaneous Annuloplasty device (Mitralign, Tewksbury, MA, USA) is a transfemoral arterial access deflectable catheter that aims at plicating the posterior mitral annulus. The device received CE mark approval in 2016. The procedure is performed by advancing a catheter retrogradely into the left ventricle and guidewires penetrate the annulus into the left atrium, where pledgets are implanted at the level of P1–P2 and P2–P3. Each pledget pair can be pulled together resulting in a segmental annuloplasty capable of shortening the annulus.

A prospective, multicenter single-arm feasibility study (ALIGN Trial) was performed on 71 patients, among which 50 underwent Mitralign implant (39). No intraprocedural death was reported, however 8% experienced pericardial tamponade, and at six months follow-up all-cause mortality was 12.2%, with seven patients requiring MitraClip implantation and one patient receiving non-emergent MV surgery, therefore the device is no longer available on the market. MR improvement was seen in 50% of patients treated, with a higher trend in patients that received two pledgets.

AccuCinch ventricular repair system

The AccuCinch ventricular repair device (40) (Ancora Heart, Santa Clara, CA) uses a retrograde approach via a transfemoral arterial access in order to implant a series of adjustable anchors within the LV wall. A cable is found below the MV annulus and it can be tightened to cinch the LV wall. Overall, it can be considered a ventriculoplasty rather than a direct
annuloplasty device, and it is in fact also being tested in patients with heart failure and without significant valvular lesions. Prospective data on this device is still missing. However, two studies, LVRECOVER and LVRESTORESA, involving around ten patients were performed, both with promising results.

**Millipede IRIS ring**

The Millipede IRIS Ring device (Millipede, Inc., Santa Rosa, CA) is a semi-rigid complete ring that is delivered through a transfemoral transseptal approach. It consists of eight helical stainless-steel anchors pre-attached to the base of the device. Each anchor rotates independently and attaches directly to the mitral annulus. Each anchor can also be retracted or unscrewed if necessary. When tensioned, adjacent anchors are brought closer together, and the crowns can be tightened individually in order to selectively reduce the most dilated portions of the MV annulus. Results on the very few first patients treated seem promising, with good reduction in MV annulus diameter (41). However, more detailed procedural and follow-up results will be further evaluated in ongoing clinical trials (42).

**Chordal replacement**

Among the different surgical repair techniques and strategies, a valuable alternative in patients affected by PMR is the so-called “respect rather than resect”, with the implantation of one or more artificial chordae. The development of less-invasive transapical chordal replacement has seen great development worldwide.

**NeoChord DS1000 System**

The NeoChord DS1000 device (43) (Neochord, Inc.,...
St. Louis Park, MN, USA) was the first device designed to allow transapical beating heart implantation of PTFE chordal loops on the MV leaflet to correct flail or prolapse, and obtained CE mark approval in 2012 Figure 5A. The initial TACT trial (44) demonstrated acute procedural success in 26 of 30 patients, with only 17 patients with MR grade <2+ at 30 days. Recently, one year follow-up of the largest International Registry comprising 213 patients was published. Procedural success was achieved in 96.7% of patients, with an overall survival at one year of 98%±1%. Composite endpoint, defined as procedural success, freedom from mortality, stroke, reintervention, recurrence of severe MR, rehospitalization and decreased of ≥ NYHA class at follow-up, was achieved in 84%±2.5% of the overall population (45,46). Furthermore, a clinical trial, ReChord, is a randomized trial currently enrolling patients comparing NeoChord transapical system vs. open surgical mitral repair in patients with degenerative MR.

While experience continues to increase, a critical drawback worth mentioning is the inability of such devices to restore even coaptation along the entire flailing/prolapsing segment. In fact, chordal loops provide focal support to the leaflet, and inter-loop prolapse and regurgitation can persist after the repair. This, together with a study conducted by Weber et al. (47), in which attachment of chordae to ventricular apex seemed to increase the risk of systolic anterior motion, may explain the relative high-rate of repair failure in some implants.

**HARPOON Device**

The HARPOON Medical System (48) (Edwards Lifesciences Corporation, Irvine, CA) is a more recent addition to this category of transcatheter repair techniques (Figure 5B). The procedure is performed through a small left thoracotomy. The device consists of a hemostatic 14Fr introducer and a delivery system that contains a pre-formed PTFE knot that anchors chords on target locations on the MV leaflet. After each knot deployment the device is withdrawn, exteriorizing two PTFE chordae. The number of knots deployed greatly depends on the extent of the flailing/prolapsing segment. The suture pairs are then threaded through a pledget and tightened under echocardiographic guidance to optimize coaptation and reduce MR grade. The device is being evaluated through a prospective, non-randomized, multicenter clinical study, the TRACER trial, in order to assess safety and performance. Thirty patients have been treated with severe PMR. Three patents required conversion to MV surgery. Twenty-seven of thirty (90%) patients reached primary endpoint of successful implantation and reduction of MR grade to
moderate-or-less. At six months, MR was moderate or less in 85% of patients, moderate in 8% and severe in the remaining 8%. Favorable cardiac remodeling was seen as a decrease in LV end-diastolic volume and left atrial volumes. Longer follow-up, together with further investigations are required. However, results seem promising, and may be linked to the preformed knot and the support to a larger section of the leaflet, as compared to the NeoChord device.

**Pipeline**

Pipeline device (Gore Medical, USA) is another transcatheter device designed for off-pump beating heart chordal replacement. The device is delivered via a transfemoral transseptal access; a guidewire is driven across the MV, within the left ventricle. Pipeline device is advanced to the papillary muscles and the distal ventricular or papillary muscle helical anchor in deployed. The following step consists in puncturing the MV leaflet in order to obtain leaflet fixation. Suture length adjustment is obtained by means of a suture lock device, under transesophageal echocardiography guidance. The artificial Neochord is tensioned in order to obtain the best coaptation and optimal MR reduction.

**Repair vs. replacement**

Despite increasing evidence of feasibility and good outcome with transcatheter repair options, almost 25% of treated patients will face at least moderate residual MR (49). Therefore, improvements in technology and in learning curves may play a pivotal role in the next years. As for surgery, whenever MV repair is possible, it should be considered as first choice treatment. In fact, several factors justify the adoption of a “repair-first strategy”, even in the percutaneous context, including: low early mortality rates, the absence of valve-related events (such as structural valve deterioration), a more respectful approach towards leaflet and annulus, higher suitability, and a shorter screening process (50). However, if a good MV repair is not expected, transcatheter MV replacement should be considered.

**Future directions**

Looking towards the future and also at the next European Society of Cardiology guidelines for the treatment of MR, it is possible to state that less invasive mitral procedures are gaining their field of interest. With the great development of technologies, together with the very important creation of Heart Teams, the various transcatheter devices need to be selected and utilized according to valve anatomy, etiology, valvular lesion and general condition of the patient, in order to offer the best possible treatment to every individual and gain a real patient-tailored approach. In fact, the Heart Team concept will further improve the decision-making process on “which device to which patient”. Considering PMR, surgery remains the treatment of choice, to date, however transcatheter interventions will likely provide a palliation in patients considered very high-risk or inoperable. On the contrary, in SMR a wider role can be further expected in the future for transcatheter repair devices (51).

A further step in the future will be to systematically combine repair techniques, such as leaflet repair or chordal replacement together with percutaneous annuloplasty, aiming at reproducing surgical long-term durable results. Furthermore, in the next few years we will see results of many trials that are currently on their way and this will hopefully help us in identifying an even clearer therapeutic line to follow.

**Conclusions**

In this manuscript we analyzed the principal devices that in the last 15 years have been invented, developed and further improved in order to provide safe and effective repair options for the treatment of MR. Some of these devices have paved the way for the growing importance of transcatheter MV repair as a novel therapeutic alternative. Such treatments have come a long way, with several trials completed and still a great number ongoing. We reviewed the main devices currently available, and their possible use according to etiology of MR and valvular lesion.

**Acknowledgments**

Funding: None.

**Footnote**

Conflicts of Interest: The authors have no conflicts of interest to declare.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons
References


Percutaneous mitral valve edge-to-edge Repair: In-hospital results and 1-year follow-up of 628 patients of the 2011-2012 pilot European Sentinel Registry. J Am Coll Cardiol 2014;64:875-84.

